Glenmede Trust’s Altimmune ALT Stock Holding History

Glenmede Trust’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,905	Closed	-$355K	–	1355
2024 Q1	$355K	Buy	+34,905	New	+$355K	﹤0.01%	1014

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Glenmede Trust's ALT Position: Q2 2024 in Review

Glenmede Trust sold out of Altimmune (ALT) in Q2 2024, closing a stake of 34,905 shares — an estimated $355K sold.

Glenmede Trust first reported a position in ALT in Q1 2024 and held it in 1 quarter. The position peaked at $355K in Q1 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q2 2024.

Glenmede Trust reported no remaining Altimmune position as of Q2 2024 after selling out during the quarter.
Glenmede Trust sold 34,905 Altimmune shares in Q2 2024, an estimated $355K.
Glenmede Trust first reported a position in Altimmune in Q1 2024 and held it in 1 quarter.
Glenmede Trust's Altimmune position peaked at $355K in Q1 2024.
173 funds tracked by Wall St. Rank held Altimmune as of Q2 2024.

Based on Glenmede Trust's 13F filing for Q2 2024, filed 14 Aug 2024.